✦ LIBER ✦

Benefits of cyclosporine microemulsion (Neoral) C2 monitoring are sustained at 1 year in de novo liver transplant recipients

✍ Scribed by J.R. Lake

Book ID: 117231264
Publisher: Elsevier Science
Year: 2001
Tongue: English
Weight: 49 KB
Volume: 33
Category: Article
ISSN: 0041-1345
DOI: 10.1016/s0041-1345(01)02317-x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

C2 monitoring of cyclosporine in de novo

C2 monitoring of cyclosporine in de novo liver transplant recipients: The clinician's perspective

✍ Federico Villamil; Stephen Pollard 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 197 KB 👁 1 views

Abbreviations: AUC 0 -6 , area under the curve for the first six hours post-dose; AUC 0 -12 , area under the curve for the first twelve hours post-dose; C 0, trough blood concentration; C 2, blood concentration at 2 hours after dose; C 4 , blood concentration at 4 hours after dose; C 6 , blood conce

Comparison of Generic Cyclosporine Micro

Comparison of Generic Cyclosporine Microemulsion versus Neoral in de Novo Renal Transplant Recipients Managed By 2-Hour Postdose Monitoring

✍ A. Sharma; C. Shekhar; M. Heer; M. Minz 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 94 KB

12-month follow-up analysis of a multice

12-month follow-up analysis of a multicenter, randomized, prospective trial in de novo liver transplant recipients (LIS2T) comparing cyclosporine microemulsion (C2 monitoring) and tacrolimus

✍ Gary Levy; Gian Luca Grazi; Fernando Sanjuan; Youmin Wu; Ferdinand Mühlbacher; D 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 113 KB 👁 2 views

For complete listing of investigators and centers, see

A 12-month, multicenter, randomized, ada

A 12-month, multicenter, randomized, adaptive design, open-label study to evaluate the benefit of C2 hour monitoring of neoral on safety and efficacy outcomes in de novo cardiac transplant recipients receiving basiliximab induction

✍ M Cantarovich; H Ross; J Arizon; J Orus; L Straatman; J Howlett; E Lage; M Cresp 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 75 KB

A 12-month, multicenter, randomized, ada

A 12-month, multicenter, randomized, adaptive design, open-label study to evaluate the benefit of C2-hr monitoring of Neoral on safety and efficacy outcomes in de novo cardiac transplant recipients receiving basiliximab induction: 6-month outcomes

✍ H. Ross; M. Cantarovich; J. Arizon; J. Orus; L. Straatman; J. Howlett; E. Lage; 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 66 KB

682: 1-Year Results of the First 120 Pat

682: 1-Year Results of the First 120 Patients Enrolled in a 3-Year Randomised, Open Label, Multi-Centre Investigator Driven Study Comparing De Novo Enteric Coated Mycophenolate Sodium with Delayed Onset Everolimus, Both Arms in Combination with Cyclosporin (Using C2 Monitoring) and Corticosteroids for the Prevention of Bronchiolitis Obliterans Syndrome in Heart-Lung, Bilateral Lung and Single Lung Transplant Recipients

✍ A.R. Glanville; C. Aboyoun; W. Klepetko; H. Reichenspurner; H. Treede; E. Versch 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 129 KB